VIVS Stock - VivoSim Labs, Inc.
Unlock GoAI Insights for VIVS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $144,000 | $109,000 | $370,000 | $1.50M | N/A |
| Gross Profit | $139,000 | $109,000 | $370,000 | $1.50M | N/A |
| Gross Margin | 96.5% | 100.0% | 100.0% | 100.0% | N/A |
| Operating Income | $-12,616,000 | $-15,086,000 | $-17,731,000 | $-11,479,000 | $-16,826,000 |
| Net Income | $-2,488,000 | $-14,671,000 | $-17,259,000 | $-11,448,000 | $-16,826,000 |
| Net Margin | -1727.8% | -13459.6% | -4664.6% | -763.2% | N/A |
| EPS | $-1.70 | $-19.25 | $-23.76 | $-15.84 | $-29.28 |
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.
Visit WebsiteEarnings History & Surprises
VIVSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 17, 2026 | — | — | — | — |
Q4 2025 | Nov 6, 2025 | $-2.28 | $-0.98 | +57.0% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | — | $-1.14 | — | — |
Q2 2025 | May 30, 2025 | $-2.28 | $-3.48 | -52.6% | ✗ MISS |
Q1 2025 | Feb 19, 2025 | $-0.21 | $-0.19 | +9.5% | ✓ BEAT |
Q4 2024 | Nov 8, 2024 | $-0.26 | $-0.14 | +46.2% | ✓ BEAT |
Q2 2024 | Jun 30, 2024 | — | $-2.74 | — | — |
Q1 2024 | Mar 31, 2024 | — | $-3.07 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-4.74 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-5.50 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-5.54 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-10.27 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-4.50 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-4.57 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-4.43 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-2.63 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-4.82 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-4.83 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-3.49 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-3.99 | — | — |
Latest News
Frequently Asked Questions about VIVS
What is VIVS's current stock price?
What is the analyst price target for VIVS?
What sector is VivoSim Labs, Inc. in?
What is VIVS's market cap?
Does VIVS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VIVS for comparison